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REVIEW
Abstract: The symptoms of restless legs syndrome (RLS) are associated with reductions in
patients’ quality of life (QoL) and mental heath. Sleep disturbance, which is often the most
troublesome symptom of RLS, may have a negative impact on patients’ daytime cognitive
abilities. Research has established a relationship between the symptoms of RLS and mood
symptoms, but causality is unclear. Some studies have indicated that the symptoms of RLS
precede those of depression or anxiety, and others relate the severity of mood symptoms to
the severity of RLS symptoms. Associations between the sleep disturbance produced by RLS
and patients’ mood symptoms have also been demonstrated. The impact of RLS symptoms
and their treatment on QoL, mental health, and cognition are reviewed herein.
Keywords: RLS, depression, anxiety, quality of life, treatment
Introduction
Restless legs syndrome (RLS) is a chronic neurological disorder. Epidemiological
studies report that RLS affects about 5%–10% of adults in the general population
(Phillips et al 2000; Ulfberg et al 2001a, 2001b). Its four key diagnostic symptoms
are (Allen et al 2003):
1. An urge to move the legs, usually accompanied or caused by uncomfortable
sensations in the legs.
2. The symptoms begin or worsen during periods of rest or inactivity.
3. The symptoms are partially or totally relieved by movement, at least as long as
the activity continues.
4. The symptoms are worsened in the evening or at night, especially at initial
presentation.
All four of these symptoms are required to make a diagnosis of RLS. In addition, the
presence of periodic leg movements (PLMs) supports the diagnosis, as 80%–90% of
patients with RLS experience PLMs (Montplaisir et al 1997). RLS may present as a
primary disorder, or secondary to other conditions such as iron deficiency anemia,
end-stage renal disease, and normal pregnancy (Allen and Earley 2001).
The etiology of RLS is not proven, but central dopaminergic dysfunction is
proposed, based on the benefits of dopamine agonists and exacerbation of RLS
symptoms by dopaminergic antagonists. Genetic linkage in familial disease and iron
metabolism offer other etiologic areas for exploration. The dopamine agonists have
demonstrated efficacy in the management of RLS (see below); indeed, a response to
dopaminergic therapy is a supportive clinical feature in the diagnosis of RLS (Allen
et al 2003). In addition, the dopamine antagonist risperidone has been reported to
induce RLS symptoms (Wetter et al 2002). In studies of potential candidate genes
involved in dopaminergic neurotransmission, links to the development of familial
RLS have been found on chromosome 12q, suggesting a link to dopamine metabolism
for this disorder (Desautels et al 2001, 2002). Finally, studies of CNS iron metabolism
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suggest impact on dopaminergic function, as CNS cellular
insufficiency of iron reduces the activity of tyrosine
hydroxylase, and may impact the expression of dopamine
transporters or receptors (Connor et al 2003).
For 60%–80% of patients with RLS, sleep disturbance
is their most distressing symptom, representing the primary
reason to seek treatment (Allen et al 2003; Hening et al
2004; Rijsman et al 2004a). Sleep deprivation impacts on
daytime functioning; for example, patients report reduced
concentration and attention, increased daytime sleepiness,
and some mood disturbance (Hening et al 2004; Rijsman et
al 2004a). In addition, several studies have demonstrated
that RLS has detrimental effects on patients’ quality of life
(QoL).
Effects of RLS on patients’ QoL
Effects in primary RLS
RLS has a detrimental impact on patients’ QoL. A large
survey of the general populations of six countries identified
people with all four diagnostic symptoms of RLS (Allen et
al 2005). The survey reported the characteristics of people
who experienced symptoms of RLS that caused moderate
distress, at least twice-weekly (Allen et al 2005). Most of
these people (85%) reported that the symptoms of RLS had
a negative impact on their daytime functioning. Most
commonly, 51% of patients agreed with the statement “These
symptoms have a negative influence on my mood”, 48%
agreed that “I lack energy when I suffer from these
symptoms”, and 40% agreed that “My daily activities are
disturbed”. Smaller proportions of patients (20%–28%)
reported that: their social life was affected by symptoms,
they were distracted from doing their job, they had a feeling
of desperation associated with the symptoms, their partner
was kept awake by their symptoms, and their personal
relationships were affected. Responses of this same group
of RLS sufferers to the Medical Outcomes Study Short Form
36-item (SF-36) questionnaire also indicated that they had
lower QoL scores than the general population norms.
Moreover, their scores on the SF-36 were similar to those
of patients with other chronic medical conditions, such as
type-2 diabetes mellitus, depression, and osteoarthritis with
hypertension (Allen et al 2005).
Similar results were produced in a survey of 85 patients
with diagnosed primary RLS (Abetz et al 2004). These
patients showed significantly lower scores (reflecting worse
QoL) than the general-population norms on all eight domains
of the SF-36 scale. The severity of RLS (assessed using the
patient version of the International Restless Legs Scale)
affected scores on most of the domains: as severity increased,
scores for role–physical, bodily pain, vitality, social
functioning, role–emotional, and mental health all decreased
(worsened). In addition, the SF-36 scores for these patients
with RLS were similar to or worse than those for patients
with other medical conditions. Patients with RLS had
significantly lower scores on seven of the eight SF-36
domains than patients who had recently experienced a
myocardial infarction. In addition, patients’ scores on
most domains were similar to those for patients with other
chronic illnesses, such as type-2 diabetes, depression,
chronic obstructive pulmonary disease with hypertension,
and osteoarthritis with hypertension (Abetz et al 2004).
Effects in patients with secondary RLS
In a survey of patients undergoing dialysis, 70% reported
all four diagnostic symptoms of RLS. The presence of these
symptoms was associated with statistically significantly
worse QoL on most of the domains of the Kidney Disease
QoL questionnaire, which comprises the eight domains of
the SF-36 and 11 domains specific to patients with kidney
disease (Mucsi et al 2005). Likewise, in a second study of
patients undergoing dialysis, those with the symptoms of
RLS showed significantly worse scores on the “emotion”
domain of the sickness impact profile (SIP) (Rijsman et al
2004b). This difference was even greater when the scores
for patients with symptoms of RLS and PLMs in sleep were
compared with the scores for patients with none of these
symptoms.
Effects of RLS on patients’ mental
health
Impact on mood
Several studies have shown an association between the
symptoms of RLS and worse mental health in comparison
with healthy controls. Studies demonstrating an association
between the symptoms of RLS and those of depression were
recently reviewed by Picchietti and Winkelman (2005).
Their review described findings from population-based
surveys and studies of patients with RLS. In one survey,
people in a representative population who had the diagnostic
symptoms of RLS had a higher incidence of depressive
symptoms and lower self-reported mental-health scores on
the SF-36 (Rothdach et al 2000). In another population-
based survey of men, respondents with the symptoms of
RLS were more likely to report depressed mood and to
complain of decreased libido in comparison with populationNeuropsychiatric Disease and Treatment 2006:2(4) 507
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norms (Ulfberg et al 2001a). A third, large population-based
survey used standard rating scales – the Hamilton
Depression Rating scale (HAM-D) and Hamilton Anxiety
Rating scale (HAM-A) – to assess depression and anxiety
in people reporting the diagnostic symptoms of RLS (Sevim
et al 2004). In this survey, people with RLS had statistically
significantly higher total scores on the HAM-A and HAM-
D than matched controls (even when three questions relating
to sleep problems were excluded from the HAM-D, and
one question from the HAM-A). Scores on most individual
items of the HAM-A and HAM-D were also statistically
significantly higher in people with RLS symptoms than in
controls. Moreover, scores on these two rating scales were
positively correlated with the severity of RLS symptoms,
whereas the presence of other comorbid diseases (eg,
hypertension, anemia, chronic kidney disease, diabetes
mellitus, and migraine) had no effects on anxiety and
depression scores. Thus, the authors concluded that the
presence of RLS symptoms “was probably the major
determining factor for the anxiety and depression scores,
with higher scores correlating with more severe RLS”
(Sevim et al 2004).
In these population-based surveys, data were obtained
from patients who reported the symptoms of RLS but had
no formal diagnosis of the disorder. These population-based
studies are consistent with studies of patients who received
a formal diagnosis of RLS (Picchietti and Winkelman 2005).
In a study of 33 patients with RLS, Saletu et al reported
statistically significantly more symptoms of depression and
anxiety (on the Zung Self-Rating Depression and Anxiety
Scales), and a lower quality of life than in healthy controls
(Saletu et al 2002a, 2002b). This study also compared EEG
changes in RLS patients and healthy controls. RLS patients
demonstrated more activity in the frontal, frontopolar, and
frontotemporal regions, a trend towards higher activity over
the parietal and left temporal regions. The EEG differences
were characterized by a significant increase in delta and
fast alpha power, a decrease in slow alpha power,
acceleration of the dominant frequency in the alpha centroid,
and slowing of the delta/theta centroid (Saletu et al 2002b).
These changes were similar to those previously reported in
patients with major depressive disorder (MDD) (Saletu et
al 1996). In addition, the greatest differences between
patients with RLS and controls were seen in those EEG
measures that have been found (in another group of patients
with depression) to be correlated with scores on the HAM-D.
Diagnoses of mood disorders
Although studies have demonstrated an increase in the
symptoms of depressed and anxious mood in patients with
the symptoms of RLS, symptom severity may not meet the
criteria for clinical diagnosis of a mood disorder or of RLS.
For example, in the large population survey reported by
Sevim et al (2004), mean score for the group of people
reporting symptoms consistent with RLS were 8 points on
the HAM-A (lower cut-off score for treatment of mild
anxiety is 18 points) and 9 points on the HAM-D (a score
of 10–13 is considered to reflect mild depression). The
authors proposed that the symptoms of depression and
anxiety were relatively mild in this survey because it was
population-based, and the RLS may have been mild, as only
30% of the people reporting symptoms of RLS had
complained about those symptoms to a healthcare
practitioner. The authors speculate that patients with a formal
diagnosis of RLS might have more severe symptoms, which
prompted them to seek treatment, and therefore may also
report more severe mood symptoms (Sevim et al 2004).
Two studies have investigated the clinical diagnosis of
mood disorders in patients with formally diagnosed RLS.
One study of 218 RLS patients investigated retrospectively
the diagnoses that patients had been given in the 5 years
prior to their referral to a sleep-disorders clinic and their
diagnosis with RLS (Banno et al 2000). Nearly half the
patients (44% of men and 46% of women) had been
diagnosed as having a mood disorder (depression NOS [not
otherwise specified] or affective psychosis). These diagnoses
were reflected in the drugs used by these patients on
presentation at the sleep clinic; antidepressants and
benzodiazepines were the most commonly prescribed drugs,
along with antihypertensives and analgesics. A second study
from Germany investigated the prevalence of anxiety and
depression by DSM-IV diagnostic criteria in patients with
a diagnosis of RLS (Winkelmann et al 2005). In 130 patients,
there were higher 12-month rates of any depressive disorder
(18% vs 9%), panic attacks (11% vs 4%), panic disorder
(9% vs 2%), and generalized anxiety disorder (GAD; 9%
vs 2%), than in controls who had a somatic illness. In most
patients, the mood disorder appeared after the onset of RLS,
suggesting that the symptoms of RLS might either initiate
or aggravate depression and anxiety. Moreover, many
patients with RLS attributed problems such as depressed
mood and reduced interest to their RLS symptoms.
Importantly, a large proportion of patients with concurrentNeuropsychiatric Disease and Treatment 2006:2(4) 508
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RLS and depression (35%) reported suicidal thoughts as a
result of their RLS symptoms (Winkelmann et al 2005).
Relationship between RLS symptoms
and mood disorders
Although the above cited studies have demonstrated that
the symptoms of depression and anxiety are often comorbid
with RLS, none was designed to demonstrate a causal
relationship between RLS and the symptoms of depression
and/or anxiety. It is possible that the two sets of symptoms
co-exist, as the prevalence of RLS and of mood and anxiety
disorders is high. Winkelmann et al from Germany suggested
that, as RLS is a highly familial disorder (Winkelmann et al
2000), the increased risk of comorbid mood symptoms and
disorders may also have a genetic component (Winkelmann
et al 2005). A common CNS mechanism for the symptoms
of RLS and depression might also relate to changes in central
dopaminergic function (Picchietti and Winkelman 2005).
Nevertheless, evidence showing that the mood disorder
appeared after the onset of RLS, and attribution of the mood
symptoms to RLS, supports the possibility of some causal
relationship in at least some patients (Winkelmann et al
2005).
Another confound is the similarity of clinical symptoms
or consequences of RLS and mood disorders (Table 1). In
particular, patients with RLS, MDD, or GAD may all present
with insomnia, daytime tiredness/fatigue, and poor daytime
concentration. This overlap in symptomatology may be
reflected in the results reported by Banno et al (2000), which
showed that many patients with RLS had previously been
given a diagnosis of a mood disorder. Some studies have
indicated a relationship between the sleep problems
associated with RLS and comorbid mood disorder (Kushida
et al 2004; Hornyak et al 2005). In addition, in one of these
studies, patients with RLS showed elevated item scores on
sleep-related symptoms of depression on the Beck
Depression Inventory but not on cognitive–affective items.
The severity of RLS was correlated with severity of sleep
problems, but not with patients’ scores for depression,
whereas the scores for sleep problems were correlated with
scores for depression (Hornyak et al 2005). Thus, one
possible reason for the apparent relationship between RLS
and mood disorders is that patients with RLS are not actually
suffering from a mood disorder, but are simply reporting
high scores on sleep-related items of mood inventories.
Chronic insomnia alone is considered to be a predictor of
later depressive or anxiety disorder (Ford and Kamerow
1989; Breslau et al 1996).
Other studies, however, have indicated that sleep-related
symptoms do not account for the increased incidence of
mood symptoms and disorders in patients with RLS, as they
report higher scores for depression and anxiety even when
questions relating to sleep problems are excluded from the
rating scales (Sevim et al 2004). In addition, when the
presence of RLS as a non-specific stressor is taken into
account, an increased prevalence of mood symptoms persists
in patients with RLS (Sevim et al 2004; Winkelmann et al
2005). The symptoms and consequences of RLS may have
direct detrimental effects on patients’ mental health, although
the nature of the relationship between RLS, sleep
disturbance, and mood disturbance/disorder requires further
study.
Cognitive effects of RLS
Few studies have reported the cognitive effects of RLS. In
a population-based survey, just under 20% of patients
reported that they had difficulty concentrating in either the
afternoon or evening (Allen et al 2005). In a small
polysomnographic study, patients with RLS showed
significant deficits on two tests designed to show prefrontal
cortical functioning, when compared with normal controls
(Pearson et al 2006). The authors concluded that these
deficits were similar to those produced by the loss of a
night’s sleep, and, therefore, might have been related to the
sleep disturbance caused by RLS. An association has also
been reported between the symptoms of attention-deficit/
hyperactivity disorder (ADHD) and RLS (Wagner et al
2004). Patients with RLS were reported to have a higher
incidence of ADHD than those with other sleep disorders
(24% vs 3%), and the severity of RLS symptoms was higher
in patients who also had symptoms of ADHD than in those
who did not. These authors proposed either that the ADHD
symptoms of inattention/hyperactivity and reduced
concentration may result from the motor symptoms of RLS,
Table 1 Symptoms of depression, generalized anxiety, and RLS
Symptom MDD GAD RLS
Sadness ++++ ++ ++/–
Insomnia +++ +++ +++
Sleepiness + +/– +/–
Tiredness/fatigue +++ ++ ++
Poor concentration ++ +++ ++
Feeling guilt/suicidal +++ + +
+ Feature of this disorder (more crosses indicates increased prominence);
– Feature not generally associated with this disorder.
Abbreviations: GAD, generalized anxiety disorder; MDD, major depressive
disorder; RLS, restless legs syndrome.Neuropsychiatric Disease and Treatment 2006:2(4) 509
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or that the two disorders might share a common
dopaminergic etiology (Wagner et al 2004).
Treatment of RLS and impact on
biopsychosocial functioning
Several therapeutic classes, particularly those that target
dopamine, have demonstrated efficacy on the symptoms of
RLS and on its sequelae, such as sleep disturbance. There
are also reports that the dopaminergic therapies reduce the
biopsychosocial effects of RLS, particularly QoL.
Treatment with ropinirole
The most extensively studied drug for RLS is the dopamine
agonist ropinirole. A series of large-scale, placebo-controlled
trials has been conducted with this drug, leading to its
approval for the treatment of moderate-to-severe primary
RLS in adults in eight countries, including the USA, France,
Switzerland, Australia, and New Zealand. There were three
clinical trials in this program – TREAT RLS 1 and 2
(Therapy with Ropinirole: Efficacy And Tolerability in RLS
1 and 2) and TREAT RLS US – which were multicenter,
randomized, double-blind, parallel-group, placebo-
controlled trials involving a total of 932 patients with
moderate-to-severe RLS, treated for 12 weeks (Trenkwalder
et al 2004; Walters et al 2004; Bogan et al 2006). Ropinirole,
in comparison with placebo, produced statistically
significant improvements in the symptoms of RLS. These
studies also demonstrated that ropinirole produced
significantly greater improvements than placebo in the
validated, disease-specific QoL scale, the RLSQoL
questionnaire. In addition, in the TREAT RLS 2 trial only
(Walters et al 2004), ropinirole produced a significantly
greater improvement in the mental-health domain of the SF-
36 than placebo, along with significant improvements in
social functioning and vitality. However, there were no
significant effects on the other domains of the SF-36 in this
trial, and no significant differences between ropinirole and
placebo on the SF-36 in the TREAT RLS 1 trial
(Trenkwalder et al 2004). The TREAT RLS US trial also
included assessments on two other scales, which
demonstrated positive effects on mood symptoms (Bogan
et al 2006). In subsets of patients with scores on the Hospital
Anxiety and Depression Scale that corresponded to at least
mildly anxious/depressed mood (≥8 on either subscale),
ropinirole produced a statistically significant reduction in
the anxiety score, compared with placebo. Ropinirole
produced a numerical, but not statistically significant,
reduction in patients’ depression scores in comparison with
placebo. In addition, ropinirole was associated with
improvements on the Profile Of Mood States scale, with a
statistically significant improvement compared with placebo
observed for the “total mood disturbance” and “vigor
activity” domains (Bogan et al 2006). The most common
adverse event during these clinical trials of ropinirole was
nausea; most adverse events were mild or moderate in
severity, and their incidence declined over time. In the
clinical trials for ropinirole, there were few reports of
augmentation of RLS symptoms, although duration of
monitoring may have been insufficient to properly assess
development of augmentation.
Treatment with pramipexole
Pramipexole has been shown to be effective in treating the
symptoms of RLS. However, there are few published data
on the effects of pramipexole on QoL measures. One study
showed that after 4 weeks of open-label use of pramipexole,
patients showed significant improvements in QoL and self-
rated depressed mood, compared with baseline, although
there were no changes in patients’ scores for self-rated
anxious mood (Saletu et al 2002c). There are also reports
of the efficacy of pramipexole in the treatment of depression
in both MDD and bipolar II disorder, albeit at doses higher
than those generally used to treat RLS (Corrigan et al 2000;
Zarate et al 2004). Pramipexole is best avoided in patients
with moderate-to-severe renal disease, since it is cleared
from the body through the kidney. In addition, augmentation
may also be a complication of pramipexole treatment in
patients who are treated for a year or more (Silber et al 2003;
Winkelman and Johnston 2004).
Treatment with L-dopa
Studies over 20 years with L-dopa have shown that this drug
is effective in the management of the symptoms of RLS
(Becker et al 1993; Trenkwalder et al 1995; Benes et al 1999;
Collado-Seidel et al 1999); it is licensed for use in the
treatment of RLS in Germany. In a double-blind, placebo-
controlled, crossover trial, QoL evaluation showed that L-
dopa treatment was associated with better life satisfaction
for patients (resulting from improvements in activities of
daily living and leisure activities) and less burden caused
by their symptoms (resulting from less severe fatigue and
depressive feelings) than placebo treatment (Benes et al
1999). Similar results were produced in another double-
blind, placebo-controlled, crossover trial, which includedNeuropsychiatric Disease and Treatment 2006:2(4) 510
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some patients with RLS secondary to renal disease, as well
as patients with primary RLS (Trenkwalder et al 1995). In
this study, L-dopa produced, overall, greater improvements
in life satisfaction and negative feelings and complaints than
placebo. In contrast, another double-blind, placebo-
controlled, crossover trial, using the same QoL assessment,
showed no significant positive effects of L-dopa on life
satisfaction or burden of symptoms in comparison with
placebo (Collado-Seidel et al 1999). An open trial of L-
dopa also showed no change in patients’ QoL or self-rated
depression and anxiety after 4 weeks of treatment (Saletu
et al 2003). Thus, current data about QoL appear to be
inconclusive for L-dopa therapy. In addition, the potential
problems of wearing-off of clinical efficacy at the end of
the dose (rebound) and augmentation of symptoms limit
the use of this therapy in 40%–80% of patients (Trenkwalder
et al 1995; Allen and Earley 1996). Therefore, a recent
treatment algorithm for RLS recommended that L-dopa
should only be used for the treatment of intermittent RLS,
as this infrequent use of L-dopa may carry less risk for the
development of augmentation or rebound (Silber et al
2004).
Treatment with pergolide
One short-term, double-blind, placebo-controlled study of
pergolide has demonstrated its efficacy in improving the
symptoms of RLS and measures of QoL (Wetter et al 1999).
Pergolide, in comparison with placebo, produced
significantly better scores for life satisfaction and negative
feelings and complaints. However, pergolide is an ergot-
related dopamine agonist, raising safety concerns typical
of ergot derivatives, such as fibrotic changes in the cardiac
valves (Pritchett et al 2002; Baseman et al 2004).
Treatment with gabapentin
Gabapentin, an analog of gamma-aminobutyric acid, was
compared with L-dopa in a small, open-label study involving
patients with RLS secondary to renal disease
(Micozkadioglu et al 2004). After 4 weeks, both treatments
improved the symptoms of RLS. Gabapentin produced
significant improvements compared with baseline on three
of the eight SF-36 domains (general health, body pain, and
social functioning). L-dopa produced significant
improvement only in the body-pain domain. Adverse events
were not reported in this study. In a small, double-blind,
placebo-controlled study of gabapentin, core RLS
symptoms, sleep and periodic limb movements were
improved (Garcia-Borreguero et al 2002). Gabapentin
produced adverse events of malaise and somnolence; but
resulted in no patient withdrawal. No measures of QoL were
included in the study.
Treatment approaches for comorbid
RLS and mood disorders
There are currently no formal treatment guidelines for the
management of comorbid RLS and mood disorders. A
practical treatment approach for RLS and depression is
suggested by Picchietti and Winkelman (2005). The initial
treatment should be based on the severity of depression. In
patients with RLS and mild depression, or depression that
seems to be a consequence of the RLS, the authors
recommend that initial therapy should target the symptoms
of RLS, as depression may be alleviated by effective
management of RLS symptoms. If MDD is moderate to
severe, or present even when the symptoms of RLS have
been managed, it should be treated with an antidepressant.
The authors recommend the use of bupropion. This choice
is partly based on the potential association between the use
of other antidepressants, particularly the selective serotonin
reuptake inhibitors (SSRIs), and the appearance of RLS.
Case histories have reported the development of RLS
symptoms in patients treated with antidepressants (Bakshi
1996; Sanz-Fuentenebro et al 1996; Hargrave and Beckley
1998; Agargun et al 2002), although larger studies have
failed to find such an association (Brown et al 2005).
Nevertheless, bupropion may prove a useful agent in some
patients with RLS; three case histories were recently
reported in which this drug was effective in improving
symptoms of both disorders in patients with comorbid
depression and RLS (Kim et al 2005).
Patients with RLS and prominent anxiety symptoms may
require treatment with an anxiolytic in addition to
dopaminergic therapy for the RLS symptoms. The
benzodiazepines, particularly clonazepam, have been used
in the treatment of RLS. Their efficacy appears to depend
mostly on reducing insomnia, rather than managing the
motor and sensory symptoms of RLS (Allen and Earley
2001; Saletu et al 2001). Thus, these drugs may be useful in
the management of RLS and anxiety, though there are
concerns about the long-term use of these agents and patients
require monitoring for dependency and declining efficacy.
As with depression, if patients have symptoms of anxiety
that are a consequence of RLS, these problems may be
ameliorated by the effective management of RLS with
dopaminergic agents.Neuropsychiatric Disease and Treatment 2006:2(4) 511
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Conclusions
Diminished QoL and mental heath are common in patients
with RLS. Sleep disturbance may also produce detrimental
effects on daytime cognitive abilities and mood. For some
patients, the effects on mental health may be so pronounced
as to reach the diagnostic criteria for major depressive
disorder or generalized anxiety disorder. In some studies
the severity of mood symptoms has been shown to correlate
positively with the severity of RLS symptoms. In addition,
some studies have indicated an association between the sleep
disturbance produced by RLS and these mood symptoms,
although sleep disturbance does not appear to account fully
for these associated mental-health problems. These problems
are important, particularly in patients who suffer severe
depressive symptoms and suicidal ideation. It is therefore
essential that these mental disorders are treated effectively.
There is some evidence from clinical trials that diminished
QoL and mood symptoms can be treated by dopamine-
agonist therapy, which is also effective in managing the
symptoms of RLS.
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